SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
Dr. Joshua Ofman was appointed as Chief Executive Officer of GRAIL, Inc., effective June 1, 2026. The appointment includes compensatory arrangements comprising a base salary of $800,000, an RSU grant of $2,000,000, and severance provisions.
View raw filing on EDGAR →Christopher P. Hsu was appointed to the Board of Directors and two Board committees (Strategy Committee and Finance and Investment Committee) effective immediately pursuant to the Cooperation Agreement with Elliott Investment Management.
View raw filing on EDGAR →The filing discloses the appointment of Nate Olmstead as Chief Financial Officer, effective July 9, 2026, replacing interim CFO Tahnil Davis. While the disclosure includes compensatory details (base salary of $600,000, target bonus of $600,000, signing bonus of $600,000, and $10.0 million in equity grants), the principal disclosed action is the appointment of a named executive officer to a material position. This is a classic exec_appointment event, material to investors as CFO changes affect financial oversight and strategy.
View raw filing on EDGAR →Eric Mullins was elected to the Board of Directors of TechnipFMC plc effective June 1, 2026, and appointed to the Audit Committee. The Board size increased from nine to ten directors.
View raw filing on EDGAR →James Jeffery Raborn was appointed to Charlotte's Web Holdings' board of directors effective May 28, 2026, as a designee of British American Tobacco pursuant to an amended Investor Rights Agreement.
View raw filing on EDGAR →Scott Stewart was appointed as Chief Financial Officer and Chief Operating Officer effective June 1, 2026, with a base salary of $400,000, bonus eligibility, a 50,000 RSU appointment grant, and severance protections. Chad Chevalier resigned as Interim CFO in connection with this appointment.
View raw filing on EDGAR →The disclosure centers on the appointment of Tina Goldenberg as Vice President and Chief Accounting Officer, effective June 15, 2026. While the filing also mentions Cathleen DeGenova's retirement, the principal action disclosed is Goldenberg's appointment to a named executive officer position. The filing includes her compensation terms (base salary of $270,000, 45% target incentive, and long-term incentive eligibility), which are material to investors assessing executive leadership changes at the company.
View raw filing on EDGAR →Eva C. Boratto has been appointed Executive Vice President and Chief Financial Officer of Cencora, Inc., effective June 29, 2026, succeeding retiring CFO James F. Cleary. The appointment includes compensatory arrangements including a $1,000,000 base salary, 100% annual bonus target, $2,000,000 sign-on bonus, and $6,000,000 RSU award.
View raw filing on EDGAR →Adam Paul was appointed as an independent director effective May 22, 2026, expanding the Board from nine to ten members. The appointment includes compensatory arrangements of $45,000 per month plus $4,000 per day for commitments exceeding four hours.
View raw filing on EDGAR →Kathleen Holmgren was appointed to the Board of Directors of Mission Produce effective as of the closing of the Mergers, filling a newly created Class III director seat with a term expiring in 2029.
View raw filing on EDGAR →The Board appointed Michael A. Rossi as Interim Chief Financial Officer and principal financial officer, effective May 29, 2026, with compensation of $375/hour via Monomoy Advisors LLC.
View raw filing on EDGAR →The filing discloses the appointment of David Friedman as a Class III director effective May 22, 2026, which is the principal action. While the section also mentions Megan Boston's resignation from the Board (though she remains CFO and secretary), the appointment is the affirmative governance action that drives the disclosure. The grant of 35,000 stock options is ancillary compensation tied to the appointment. Board composition changes are material to investors assessing corporate governance.
View raw filing on EDGAR →The filing discloses the appointment of Akiko Moni Miyashita as a director of Averin Capital Acquisition Corp., effective May 28, 2026. The principal action is a person taking a board role, with detailed biographical information provided. As a SPAC director appointment, this is material to investors assessing the company's governance and business combination prospects.
View raw filing on EDGAR →The filing discloses both the retirement of Anna T. Chew as CFO and the appointment of Kevin S. Miller as her successor, effective June 1, 2026. While both events occur, the principal action emphasized in the disclosure structure is Miller's appointment to the CFO role, with detailed background on his qualifications and compensation ($430,000 annual base). The retirement is presented as the context for the appointment rather than as the primary event. This is material as it involves a change in the Company's chief financial officer.
View raw filing on EDGAR →SkyAI, Inc. entered into an employment agreement with Arthur Levine on May 22, 2026, appointing him as Chief Financial Officer effective immediately. The filing discloses his background, compensation structure ($400,000 base salary plus 50% bonus), equity eligibility, and severance terms. This is a material executive appointment requiring disclosure under Item 5.02 and Item 1.01.
View raw filing on EDGAR →The filing discloses both the resignation of CFO Eric Sherb (May 26, 2026) and the appointment of Dr. Narasimhan Mani as Interim CFO effective the same date. While both events are disclosed, the principal action emphasized is the appointment of Dr. Mani, with substantial detail provided about his qualifications, background, and experience in pharmaceutical and healthcare finance. The appointment of an interim CFO to a critical financial leadership role is material to investors assessing management continuity and financial oversight.
View raw filing on EDGAR →Adrian Rodriguez was appointed as Executive Vice President and Chief Operating Officer effective May 26, 2026, transitioning from his interim role since November 2025. This is a permanent appointment to a material C-suite position (COO) at the registrant, which would affect a reasonable investor's assessment of management continuity and operational leadership. The disclosure centers on the appointment action itself, not compensation terms (which remain pending determination).
View raw filing on EDGAR →Jeffrey K. Schomburger was appointed as Chief Executive Officer of Tyson Foods, effective October 4, 2026, with a compensation package including a $1.6M base salary, $11M long-term incentive target, and a $2.8M restricted stock unit grant. Donnie King departed from the CEO role as part of this transition.
View raw filing on EDGAR →John B. Wood has returned from medical leave and resumed his full duties as President, CEO, and Chairman of the Board effective May 28, 2026. While this involves the resumption of an existing executive role rather than a new appointment, the disclosure centers on Wood's return to active leadership after an interim period where other executives held his responsibilities. The materiality stems from the restoration of the CEO and Chairman roles to their permanent holder, which affects the governance and leadership structure of the company.
View raw filing on EDGAR →Stefan Demmerle was appointed to serve as Vice President, President and General Manager of Battery Energy Systems, and Chief Technology Officer of BorgWarner Inc., effective July 1, 2026. This represents a material promotion to a senior executive role overseeing a strategic business unit (Battery Energy Systems) and the company's technology function. The appointment of a named executive to a significant new position is a material corporate event affecting investor assessment of management and strategic direction.
View raw filing on EDGAR →Taylor Patton's appointment as Chief Commercial and Marketing Officer is the principal disclosed action. While Henry L. Charlton's transition to a different senior role is also mentioned, the filing centers on the succession event—Patton succeeding Charlton in a C-suite commercial leadership position. This executive appointment at a major medical device company is material to investors assessing management continuity and strategic direction.
View raw filing on EDGAR →Red River Bancshares appointed two new directors, A. Peyton Bush, IV and R. Chance DeWitt, M.D., to the board effective May 28, 2026, with independence determinations and committee assignments disclosed.
View raw filing on EDGAR →The filing discloses the appointment of Eric Batis to the Board of Directors on May 21, 2026, as the principal action. While the section also mentions the resignations of two directors (Stefani Danielle Carter and Rebecca Musser), the substantive focus and detail is on Batis's appointment, his qualifications as COO of Ashford Inc., and his extensive operational and investment background. The appointment of a new board member with significant operational experience at a related company is material to investors assessing board composition and governance.
View raw filing on EDGAR →Peter Pitts was appointed as a director of Brainstorm Cell Therapeutics effective May 25, 2026, expanding the Board from seven to eight directors. The appointment was approved by the Board and disclosed via press release on May 28, 2026.
View raw filing on EDGAR →Andrew Safran was appointed to the Board of Directors of Ferrellgas, Inc. on May 21, 2026, bringing significant energy and investment banking experience. Pamela A. Breuckmann was appointed to Vice Chair of the Board. These board appointments and promotion represent material governance changes affecting the company's strategic direction.
View raw filing on EDGAR →The filing discloses the appointment of Jason B. Rush as Chairman of the Board on May 27, 2026, following his election to the Board at the May 7, 2026 annual meeting. While Rush was already serving as President and CEO (appointed January 1, 2026), the principal disclosed action here is his elevation to Chairman, a material executive appointment. The extensive employment history and compensation reference underscore the significance of this role change.
View raw filing on EDGAR →The filing discloses the appointment of Matt McLaughlin as Chief Executive Officer of comScore, Inc., announced via press release on May 28, 2026. The appointment of a CEO is a material executive change that would affect a reasonable investor's assessment of the company's leadership and direction. Although disclosed under Item 7.01 (Regulation FD Disclosure) rather than the typical Item 5.02, the substance is clearly an executive appointment.
View raw filing on EDGAR →Tim McHugh was elected to the Board of Directors of FrontView REIT, Inc., effective May 28, 2026. McHugh brings substantial experience as Co-President and CFO of Welltower Inc., a public REIT, and qualifies as independent under NYSE listing standards.
View raw filing on EDGAR →Three former American Woodmark directors—Andrew Cogan, Philip Fracassa, and Daniel Hendrix—were appointed as independent directors to MasterBrand's Board effective at the merger closing, expanding the Board from 8 to 11 directors as part of post-acquisition governance integration.
View raw filing on EDGAR →Scott M. Ferris was appointed as a Class III Director on May 22, 2026, following the Board's decision to increase board size from 8 to 9 members. Ferris was also appointed to the Audit Committee and Operational Risk Committee.
View raw filing on EDGAR →The filing discloses the appointment of Zachary Roberts, M.D., Ph.D. as President and Chief Executive Officer effective July 1, 2026, replacing David Chang. While the section also covers Dr. Chang's departure and compensatory arrangements for Dr. Roberts, the principal disclosed action centers on the appointment of a new CEO—a material executive change. The filing provides detailed background on Dr. Roberts' qualifications and his appointment to the Board, making the appointment the salient event.
View raw filing on EDGAR →BiomX appointed Roy Rousso as Chief Business Officer effective July 1, 2026, with detailed compensation terms including a monthly consulting fee of $11,900, performance bonus eligibility up to 50%, and an equity award of 200,000 shares vesting over three years. This is a material executive appointment disclosing a senior officer role and significant compensatory arrangements that would affect investor assessment of the company's leadership and capital structure.
View raw filing on EDGAR →The filing discloses both the resignation of CFO Lili Hu and the appointment of Wei Li as CFO and Board member effective immediately on May 28, 2026. While both events occur, the principal disclosed action centers on the appointment of Ms. Li to the CFO role and Board, with detailed background on her qualifications and experience. The appointment of a CFO is material to investors as it affects the company's financial leadership and governance.
View raw filing on EDGAR →While the filing discloses both a director resignation (David Enholm) and an appointment (Tyler Hassen), the principal action is the appointment of the CEO to the Board. The resignation is explicitly stated as amicable and unrelated to disagreement, and Mr. Enholm continues as CFO. The appointment of the sitting CEO to the Board is the material governance event that would affect investor assessment of the company's leadership structure.
View raw filing on EDGAR →The filing discloses two executive events: the departure of President and CEO David Moon (effective May 26, 2026) and the appointment of Alex Buehler as Interim President and CEO on the same date. While both events are disclosed, the principal action and focus of the disclosure is Buehler's appointment to lead the company during the transition to a permanent successor. The appointment of an interim CEO is material to investors as it addresses continuity of leadership and operational control.
View raw filing on EDGAR →The filing discloses the appointment of Bradley Williams as Vice President of Government Affairs, a named executive position. The company explicitly states this appointment "supports the Company's vision of establishing the Company as the U.S. leader at the front-end of the nuclear fuel cycle and deepens its presence in Washington, D.C.," indicating strategic importance. While disclosed under Item 7.01 (Regulation FD Disclosure) rather than the typical Item 5.02, the substance is clearly an executive appointment material to investors assessing the company's leadership and strategic direction.
View raw filing on EDGAR →The Board of Western Digital unanimously appointed Manuvir Das as a director and Audit Committee member on May 26, 2026. This appointment affects the company's corporate governance and oversight structure.
View raw filing on EDGAR →EnerSys announced a segment realignment effective May 28, 2026, resulting in material reassignments of executive roles and responsibilities for three named officers: Keith D. Fisher (President, Network & Infrastructure Solutions), Chad C. Uplinger (President, Industrial Mobility Solutions), and Mark E. Matthews (Chief Technology Officer and President, Precision Power Solutions).
View raw filing on EDGAR →Mitchell Arends was appointed Senior Vice President and Chief Supply Chain Officer, effective June 22, 2026, succeeding Jason Reiman who is retiring from the role. The appointment of an executive to this material operational position is disclosed across Items 5.02 and 7.01.
View raw filing on EDGAR →The filing discloses the appointment of Andrew Miller, Ph.D. to the Board of Directors on May 27, 2026, following unanimous Board approval. The disclosure includes detailed biographical information highlighting his extensive biotechnology leadership experience (founder of Karuna Therapeutics, former CEO, COO, and current board member of Kyverna Therapeutics), his compensation arrangements (initial and annual equity grants plus cash retainers), and committee assignments. This is a clear executive appointment event material to investors assessing board composition and governance.
View raw filing on EDGAR →The filing discloses the appointment of William Harkins to the role of Executive Vice President and Chief Financial Officer effective June 15, 2026, along with compensatory arrangements including a $610,000 base salary, bonus and equity adjustments, and a $500,000 one-time restricted stock award. While the filing also mentions Kenneth Krause's resignation as CFO, the principal disclosed action centers on Harkins' appointment to a senior executive role with material compensation details, making exec_appointment the most salient classification.
View raw filing on EDGAR →The filing discloses the appointment of Stephen J. McAnena as President and Chief Executive Officer effective June 1, 2026, and the election of Tony DeSantis as a non-employee director. While the section also includes details on compensatory arrangements and a new Executive Severance Plan, the principal disclosed action centers on these executive and board appointments. The appointment of a new CEO is a material event that would affect a reasonable investor's assessment of the company's leadership and governance.
View raw filing on EDGAR →Thomas Sweet was appointed by the Board as Chair of the Audit Committee, effective May 26, 2026. This appointment is material given its impact on governance and oversight of internal controls, particularly in light of the company's ongoing remediation of material weaknesses in internal control over financial reporting.
View raw filing on EDGAR →Agilent appointed Tim Downs as Vice President, Chief Accounting Officer and principal accounting officer, effective May 20, 2026, following the retirement of Rodney Gonsalves.
View raw filing on EDGAR →Mr. Stopko was appointed to a director or officer position. The filing references incorporation by reference to Item 7.01 for substantive disclosure and directs readers to the company's 10-K for details on his role, compensation, and governance status.
View raw filing on EDGAR →Primis Financial Corp. appointed two new directors, Scott R. Gamble and J. Brock Saunders, to the Board of Primis Financial Corp. and its subsidiary bank, effective May 21, 2026, with specified committee assignments. The appointments follow the non-re-election of two departing directors and reflect changes to board composition.
View raw filing on EDGAR →Synopsys appointed Jesse Cohn to its Board of Directors effective June 1, 2026, pursuant to a Cooperation Agreement with Elliott Investment Management dated May 26, 2026. Mr. Cohn was also appointed to the Corporate Governance and Nominating Committee and received standard director compensation and indemnification arrangements.
View raw filing on EDGAR →Ash Walia was appointed as Chief Financial Officer of Six Flags Entertainment Corporation, effective June 17, 2026, with a base salary of $690,000, target annual incentive of 100%, restricted stock units valued at $1,250,000, and annual equity grants of $1,869,000.
View raw filing on EDGAR →Erik Lundgren was appointed as Chief Executive Officer effective June 1, 2026, with a detailed employment agreement including a base salary of $685,000, performance bonuses, and an equity grant of 1,000,000 options. Dr. Daniel Vitt resigned as CEO concurrent with this appointment.
View raw filing on EDGAR →Six directors—Joseph Durnford, Ernest Miller, Jon Ryan, Mike Maggard, Dan Collingridge-Padbury, and Jonathan Nickell—were appointed to the board of Oceanhawk in connection with the IPO on May 20, 2026, with assignments to audit and compensation committees.
View raw filing on EDGAR →